Want to see HK:2289 full AI Analyst Report?
2289 Stock Chart & Stats
HK$7.31
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$7.31
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$4.20 - HK$8.00
Previous CloseN/A
Volume50.00K
Average Volume (3M)283.00
Market Cap
HK$594.00M
Enterprise ValueHK$2.42K
Total Cash (Recent Filing)HK$753.92M
Total Debt (Recent Filing)HK$2.09B
Price to Earnings (P/E)11.2
Beta-0.21
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.25%
Share Statistics
EPS (TTM)0.42
Shares Outstanding108,000,000
10 Day Avg. Volume100
30 Day Avg. Volume283
Financial Highlights & Ratios
PEG Ratio-1.24
Price to Book (P/B)1.15
Price to Sales (P/S)0.16
P/FCF Ratio2.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Recent Cash GenerationThe sharp improvement in operating and free cash flow supports earnings quality and provides internal funding for operations, debt service, and investment. This is a meaningful financial strength, although consistency across years remains important.
Improved Gross MarginSustained gross-margin expansion indicates better economics in the distribution business, potentially from product mix, procurement, or operating improvements. Even modest margin gains can support cash generation and profitability when applied to stable revenue.
Stable Revenue BaseA stable sales base provides a degree of business visibility and suggests continued demand for the company’s pharmaceutical distribution activities. Modest recent growth can support operating leverage if margin improvements and cost control persist.
Bears Say
Sharp Increase In LeverageHigher debt financing has driven leverage materially above the prior year while equity remained fairly flat. This increases interest and refinancing risk, limits financial flexibility, and makes the business more sensitive to weaker earnings or cash flow.
Thin And Declining ProfitabilityVery low net margins leave limited protection against cost increases, pricing pressure, or financing expense. The decline from 2022 levels and lower 2025 net income indicate that steady revenue has not translated into durable earnings growth.
Inconsistent Earnings And Cash Flow TrendAlthough 2025 cash generation was strong, the prior volatility reduces confidence that performance is repeatable. Combined with negative EPS growth, this suggests earnings conversion and operating performance remain uneven over the medium term.
Charmacy Pharmaceutical Co., Ltd. Class H News
2289 FAQ
What was Charmacy Pharmaceutical Co., Ltd. Class H’s price range in the past 12 months?
Charmacy Pharmaceutical Co., Ltd. Class H lowest stock price was HK$4.20 and its highest was HK$8.00 in the past 12 months.
What is Charmacy Pharmaceutical Co., Ltd. Class H’s market cap?
Charmacy Pharmaceutical Co., Ltd. Class H’s market cap is HK$594.00M.
When is Charmacy Pharmaceutical Co., Ltd. Class H’s upcoming earnings report date?
Charmacy Pharmaceutical Co., Ltd. Class H’s upcoming earnings report date is Aug 31, 2026 which is in 5 days.
How were Charmacy Pharmaceutical Co., Ltd. Class H’s earnings last quarter?
Charmacy Pharmaceutical Co., Ltd. Class H released its earnings results on Mar 27, 2026. The company reported HK$0.249 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Charmacy Pharmaceutical Co., Ltd. Class H overvalued?
According to Wall Street analysts Charmacy Pharmaceutical Co., Ltd. Class H’s price is currently Overvalued.
Does Charmacy Pharmaceutical Co., Ltd. Class H pay dividends?
Charmacy Pharmaceutical Co., Ltd. Class H pays a Annually dividend of HK$0.344 which represents an annual dividend yield of 6.25%. See more information on Charmacy Pharmaceutical Co., Ltd. Class H dividends here
What is Charmacy Pharmaceutical Co., Ltd. Class H’s EPS estimate?
Charmacy Pharmaceutical Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Charmacy Pharmaceutical Co., Ltd. Class H have?
Charmacy Pharmaceutical Co., Ltd. Class H has 108,000,000 shares outstanding.
What happened to Charmacy Pharmaceutical Co., Ltd. Class H’s price movement after its last earnings report?
Charmacy Pharmaceutical Co., Ltd. Class H reported an EPS of HK$0.249 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Charmacy Pharmaceutical Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2289
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Charmacy Pharmaceutical Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.96%
12-Months-Change
Fundamentals
Return on Equity
6.25%
Trailing 12-Months
Asset Growth
19.90%
Trailing 12-Months
Company Description
Charmacy Pharmaceutical Co., Ltd. Class H
Charmacy Pharmaceutical Co., Ltd. serves as a prominent distributor of pharmaceutical products across the People's Republic of China. The company's comprehensive portfolio includes Western medications, traditional Chinese patent medicines, and various healthcare items, along with associated advisory services. These are supplied to both wholesale distributors and retail pharmacies. Furthermore, Charmacy operates "Charmacy e-Medicine," its proprietary B2B digital platform, which enables clients to efficiently place orders, make inquiries, and process payments online. Founded in 1984, the firm maintains its headquarters in Shantou, PRC. It was formerly known as Chuangmei Pharmaceutical Co., Ltd. until its official renaming to Charmacy Pharmaceutical Co., Ltd. in July 2016.
Technical Analysis
China Health Group
―
Shanghai Pharmaceuticals Holding Co
―
Sinopharm Group Co
―
IVD Medical Holding Limited
―
Medlive Technology Co., Ltd.
―